FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions-Reference-Cited by-同舟云学术

FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions

Published:2023-09-22 Issue:17 Volume:24 Page:1833-1837
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Neureiter Daniel¹²,Ellinghaus Peter³,Ocker Matthias⁴⁵⁶

Affiliation:

1. Institute of Pathology, Paracelsus Medical University/University Hospital Salzburg (SALK), Salzburg, Austria

2. Cancer Cluster Salzburg, Salzburg, Austria

3. Global Clinical Development Oncology, Merck Healthcare KGaA, Darmstadt, Germany

4. Medical Department, Division of Hematology, Oncology, and Cancer Immunology Campus Charité Mitte, Charité University Medicine Berlin, Berlin, Germany

5. EO Translational Insights Consulting GmbH, Berlin, Germany

6. Tacalyx GmbH, Berlin, Germany

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2259802

Reference25 articles.

1. The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma

2. Targeted therapies in advanced biliary tract cancers—a narrative review

3. Genomic spectra of biliary tract cancer

4. Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?

5. Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies to enhance the response of liver cancer to pharmacological treatments;American Journal of Physiology-Cell Physiology;2024-07-01